Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection

Graham R Foster, Stephen Pianko, Ashley Brown, Daniel M Forton, Ronald G Nahass, Jacob George, Eleanor Barnes, Diana Brainard, Benedetta Massetto, Ming Lin, Bin Han, John G McHutchison, G Mani Subramanian, Curtis Cooper, Kosh Agarwal

Research output: Contribution to journalArticleResearchpeer-review

169 Citations (Scopus)

Abstract

Background and Aims We conducted an open-label, randomized, phase 3 trial to determine the efficacy and safety of sofosbuvir and ribavirin, with and without peginterferon-alfa, in treatment-experienced patients with cirrhosis and hepatitis C virus (HCV) genotype 2 infection and treatment-naive or treatment-experienced patients with HCV genotype 3 infection. Methods The study was conducted at 80 sites in Europe, North America, Australia, and New Zealand Patients were randomly assigned (1:1:1) to groups given sofosbuvir and ribavirin for 16 weeks (n = 196); sofosbuvir and ribavirin for 24 weeks (n = 199); or sofosbuvir, peginterferon-alfa, and ribavirin for 12 weeks (n = 197). The primary end point was the percentage of patients with HCV RNA
Original languageEnglish
Pages (from-to)1462 - 1470
Number of pages9
JournalGastroenterology
Volume149
Issue number6
DOIs
Publication statusPublished - 2015

Cite this